96 related articles for article (PubMed ID: 20841935)
21. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
23. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Tendo M; Yashiro M; Nakazawa K; Yamada N; Sawada T; Ohira M; Hirakawa K
Cancer Lett; 2006 Dec; 244(2):247-51. PubMed ID: 16448745
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
25. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
26. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
27. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue].
Ono M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603
[TBL] [Abstract][Full Text] [Related]
28. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
29. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
30. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
31. Potent antitumor effect of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine on peritoneal dissemination models of gastrointestinal cancers.
Miura S; Endo Y; Yoshimura Y; Endo M; Yonemura Y; Sasaki T
Oncol Rep; 2002; 9(6):1319-22. PubMed ID: 12375041
[TBL] [Abstract][Full Text] [Related]
32. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
33. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
34. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
35. [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
Zeng QL; Chu ZH; Zhou K; Luo XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):376-8. PubMed ID: 18636363
[TBL] [Abstract][Full Text] [Related]
36. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
[TBL] [Abstract][Full Text] [Related]
37. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
38. [Partial response of liver metastasis from colon cancer following intermittent oral administration of TS-1 after intra-hepatic arterial single injection of CDDP, doxorubicin and 5-FU].
Oguro A; Nanri M; Miyamoto Y; Ujiie K; Iitaka D; Suzuki T; Koh T; Kobayashi S; Yamazaki J
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1669-71. PubMed ID: 17108740
[TBL] [Abstract][Full Text] [Related]
39. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
[TBL] [Abstract][Full Text] [Related]
40. [Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
Okuda N; Takahashi K; Yagi Y; Ichikawa K; Yamaoka T; Katou T; Kodera Y
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1659-61. PubMed ID: 17940385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]